RT Journal Article
SR Electronic
A1 Vinall, Phil
T1 IMS III: Results and Perspective
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 1
SP 28
OP 29
DO 10.1177/155989771301014
UL http://mdc.sagepub.com/content/13/1/28.abstract
AB Stroke is the second leading cause of death with 16 million strokes occurring worldwide each year. The randomized Interventional Management of Stroke III Trial [IMS III] study was designed to test whether endovascular therapy following IV tPA was more efficacious than IV tissue plasminogen activator (tPA) alone [Broderick JP et al. N Engl J Med 2013].